Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

For pharma services firms, big assets can pose major risks

Despite a spotty track record, contract development and manufacturing organizations push on in their acquisition of drugmakers’ factories

by Rick Mullin
October 13, 2019 | A version of this story appeared in Volume 97, Issue 40
A photo of two plant workers walking down the midway of a huge fine chemical factory.

Credit: Evonik | Eli Lilly and Company recently renewed a service contract that accompanied the sale of its Lafayette, Indiana, manufacturing complex to Evonik Industries in 2010. Evonik now also serves about 20 other customers at the facility.

Article:

This article has been sent to the following recipient: